Abstract

The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.

Other References

• Hild, Gunter., "An Article Concerning Rectal Bismuth Therapy in Angina Tonsillaris, Pharyngitis and Inflammation of Mucous Membrane of the Mouth," Medizinische, 40:1879-1886 (1959). English translation of entire article included
• Sun et al., "Bismuth Antiulcer Complexes," Topics in Biological Inorganic Chemistry, 2:159-185 (1999)
• Brian et al., "Bismuth Compounds and Preparations with Biological or Medicinal Relevance" Chemical Reviews, 99(9) :2601-2657 (1999)
• Israel et al., "Topical Dehydroascorbic Acid (DHA) Reduces Moderate to Severe Mucositis in the Hamster Acute Radiation Model," Program/Proceedings of the American Society of Clinical Oncology. Thirty-sixth Annual Meeting, New Orleans, LA, May 20-23, 200